FIELD: chemistry.
SUBSTANCE: present invention relates to novel quinoline or quinazoline derivatives of general formula 
Ib, where R1 is C1-6-alkyl or C1-6-alkoxy; X is N or CH; R3 and R4 independently denote hydrogen, C1-6-alkyl, C1-6-alkylsulphonyl or a group of formula 
(IIa), where A is oxygen or sulphur; D is -(CH2)t, -(CH2)tO- or -O(CH2)t, where t equals 0, 1, 2, 3 or 4; and E is C1-6-alkyl, C3-7-cycloalkyl, or a 3-7-member monocyclic aromatic ring or a 6-10-member bicyclic aromatic ring in which 1-3 carbon atoms in the ring(s) are optionally substituted with a heteroatom which is independently selected from nitrogen, oxygen and sulphur, (optionally substituted with 1 or 2 substitutes independently selected from halogen, C1-6-alkyl, CF3, cyano, hydroxy and C1-6-alkoxy); or a group of formula 
(IIb), where A is oxygen or sulphur; D is -(CH2)t-, -(CH2)tO- or -O(CH2)t, where t equals 0, 1, 2, 3 or 4; and E is C1-6-alkyl, C3-7-cycloalkyl, or a 3-7-member monocyclic aromatic ring or a 6-10-member bicyclic aromatic ring in which 1-3 carbon atoms in the ring(s) are optionally substituted with a heteroatom which is independently selected from nitrogen, oxygen and sulphur (optionally substituted with 1 or 2 substitutes independently selected from halogen, C1-6-alkyl, CF3, cyano, hydroxy and C1-6-alkoxy); or R3 and R4 together with the nitrogen atom with which they are bonded form a 3-7-member ring or a 6-10-member bicyclic ring which can be saturated, partially saturated or unsaturated and contain 1, 2 or 3 heteroatoms selected from nitrogen, sulphur and oxygen, where each group is optionally substituted with 1 or 2 substitutes selected from oxo, C1-6-alkyl, C1-6-alkoxy, aryl and aryl-C1-6-alkyl (where aryl and aryl-C1-6-alkyl are also optionally substituted with 1 or 2 with C1-6-alkyls or C1-6-alkoxy). The invention also relates to use of formula Ib compounds in preparing a medicinal agent, to a pharmaceutical composition based on formula Ib compound and preparation method thereof.
EFFECT: obtaining novel quinoline and quinazoline derivatives having high affinity to 5-HT1-receptors.
12 cl, 171 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONDENSED TRICYCLIC DERIVATIVES FOR TREATING PSYCHOTIC DISORDERS | 2005 |
|
RU2409582C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATING AGENTS | 2002 |
|
RU2305099C2 |
| PHOSPHOINDOLES AS HIV INHIBITORS | 2005 |
|
RU2393163C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| PYRROLOPYRIDINES EFFECTIVE AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2435769C2 |
| CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | 2011 |
|
RU2565596C2 |
| 2-PROPEN-1-ONS AS HSP-70 INDUCTORS | 2005 |
|
RU2341522C2 |
| DERIVATIVES OF 1-(4-BENZYLPIPERAZIN-1-YL)-3-PHENYLPROPENONE AND THEIR USE, PHARMACEUTICAL COMPOSITION AND METHOD INHIBITING CHEMOKINE RECEPTORS (CCR-1) | 2003 |
|
RU2347782C2 |
| THIENO[3,2-d]PYRIMIDINE DERIVATIVES, POSSESSING INHIBITING ACTION WITH RESPECT TO PROTEINKINASE | 2011 |
|
RU2524210C2 |
